{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Interaction+Potentiation", "query": { "condition": "Drug Interaction Potentiation" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T01:50:29.008Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03259542", "title": "Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interaction Potentiation", "Healthy" ], "interventions": [ { "name": "Mifepristone 300 MG", "type": "DRUG" }, { "name": "Itraconazole 100 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "18 Years to 65 Years · Male only" }, "enrollment_count": 33, "start_date": "2017-08-09", "completion_date": "2017-12-11", "has_results": false, "last_update_posted_date": "2018-02-22", "last_synced_at": "2026-05-22T01:50:29.008Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03259542" }, { "nct_id": "NCT03886701", "title": "Doravirine, Rifapentine and Isoniazid Interaction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Latent Tuberculosis", "Human Immunodeficiency Virus", "Rifamycins Causing Adverse Effects in Therapeutic Use", "Drug Interaction Potentiation" ], "interventions": [ { "name": "Doravirine (DOR)", "type": "DRUG" }, { "name": "Rifapentine (RPT)", "type": "DRUG" }, { "name": "Isoniazid (INH)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Walter K. Kraft", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 11, "start_date": "2019-04-22", "completion_date": "2019-05-20", "has_results": true, "last_update_posted_date": "2020-03-27", "last_synced_at": "2026-05-22T01:50:29.008Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03886701" }, { "nct_id": "NCT02191358", "title": "YouScript IMPACT Registry", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adverse Drug Events", "Adverse Drug Reactions", "Drug Interaction Potentiation", "Drug Metabolism, Poor, CYP2D6-RELATED", "Drug Metabolism, Poor, CYP2C19-RELATED", "Cytochrome P450 Enzyme Deficiency", "Cytochrome P450 CYP2D6 Enzyme Deficiency", "Cytochrome P450 CYP2C9 Enzyme Deficiency", "Cytochrome P450 CYP2C19 Enzyme Deficiency", "Cytochrome P450 CYP3A Enzyme Deficiency", "Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant", "Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant", "Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant" ], "interventions": [], "intervention_types": [], "sponsor": "Genelex Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 800, "start_date": "2014-10", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2017-03-01", "last_synced_at": "2026-05-22T01:50:29.008Z", "location_count": 7, "location_summary": "Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Towson", "state": "Maryland" }, { "city": "Fall River", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02191358" }, { "nct_id": "NCT01324752", "title": "A Drug-Drug Interaction Study of Losartan and PA21", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interaction Potentiation" ], "interventions": [ { "name": "PA21 and Losartan with Food", "type": "DRUG" }, { "name": "No PA21; Losartan with food", "type": "DRUG" }, { "name": "PA21 with food and Losartan 2 hours later", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vifor Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "20 Years to 50 Years" }, "enrollment_count": 36, "start_date": "2011-03", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2012-12-21", "last_synced_at": "2026-05-22T01:50:29.008Z", "location_count": 1, "location_summary": "Anaheim, California", "locations": [ { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01324752" }, { "nct_id": "NCT02500667", "title": "A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interaction Potentiation" ], "interventions": [ { "name": "N91115", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nivalis Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 15, "start_date": "2015-06", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2016-11-07", "last_synced_at": "2026-05-22T01:50:29.008Z", "location_count": 1, "location_summary": "Lakewood, Colorado", "locations": [ { "city": "Lakewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02500667" }, { "nct_id": "NCT01438359", "title": "A Drug-Drug Interaction Study of Furosemide and PA21", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PA21 and Furosemide with food", "type": "DRUG" }, { "name": "No PA21; Furosemide with food", "type": "DRUG" }, { "name": "PA21 with food and Furosemide 2hrs later", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vifor Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "20 Years to 50 Years" }, "enrollment_count": 42, "start_date": "2011-07", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2011-09-30", "last_synced_at": "2026-05-22T01:50:29.008Z", "location_count": 1, "location_summary": "Anaheim, California", "locations": [ { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01438359" }, { "nct_id": "NCT01477411", "title": "A Drug-Drug Interaction Study of Digoxin and PA21", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interaction Potentiation" ], "interventions": [ { "name": "PA21", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vifor Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "20 Years to 50 Years" }, "enrollment_count": 42, "start_date": "2011-11", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2012-01-18", "last_synced_at": "2026-05-22T01:50:29.008Z", "location_count": 1, "location_summary": "Anaheim, California", "locations": [ { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01477411" }, { "nct_id": "NCT01452906", "title": "A Drug-Drug Interaction Study of Omeprazole and PA21", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PA21 and Omeprazole with food", "type": "DRUG" }, { "name": "No PA21; Omeprazole with food", "type": "DRUG" }, { "name": "PA21 with food, Omeprazole 2hrs later", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vifor Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "20 Years to 50 Years" }, "enrollment_count": 45, "start_date": "2011-09", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2011-12-12", "last_synced_at": "2026-05-22T01:50:29.008Z", "location_count": 1, "location_summary": "Anaheim, California", "locations": [ { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01452906" }, { "nct_id": "NCT02378220", "title": "Pharmacogenetic Testing Among Home Health Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adverse Drug Events", "Adverse Drug Reactions", "Drug Interaction Potentiation", "Drug Metabolism, Poor, CYP2D6-RELATED", "Drug Metabolism, Poor, CYP2C19-RELATED", "Cytochrome P450 Enzyme Deficiency", "Cytochrome P450 CYP2D6 Enzyme Deficiency", "Cytochrome P450 CYP2C9 Enzyme Deficiency", "Cytochrome P450 CYP2C19 Enzyme Deficiency", "Cytochrome P450 CYP3A Enzyme Deficiency", "Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant", "Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant", "Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant" ], "interventions": [ { "name": "Pharmacogenetic testing", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Genelex Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 110, "start_date": "2015-03", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2019-09-20", "last_synced_at": "2026-05-22T01:50:29.008Z", "location_count": 1, "location_summary": "Searcy, Arkansas", "locations": [ { "city": "Searcy", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02378220" }, { "nct_id": "NCT01477424", "title": "A Drug-Drug Interaction Study of Warfarin and PA21", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interaction Potentiation" ], "interventions": [ { "name": "PA21", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vifor Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "20 Years to 50 Years" }, "enrollment_count": 45, "start_date": "2011-11", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2012-02-16", "last_synced_at": "2026-05-22T01:50:29.008Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01477424" } ] }